Publication: Current Status of Peritoneal Surface Malignancy in Thailand
Issued Date
2019-02-28
Resource Type
ISSN
09766952
09757651
09757651
Other identifier(s)
2-s2.0-85062299967
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Indian Journal of Surgical Oncology. Vol.10, (2019), 29-32
Suggested Citation
Chayanit Sirisai, Asada Methasate Current Status of Peritoneal Surface Malignancy in Thailand. Indian Journal of Surgical Oncology. Vol.10, (2019), 29-32. doi:10.1007/s13193-018-0858-z Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51854
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Current Status of Peritoneal Surface Malignancy in Thailand
Author(s)
Abstract
© 2018, Indian Association of Surgical Oncology. Peritoneal dissemination negatively affects the survival of cancer patients. Comprehensive treatment comprising of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) introduced by Dr. Paul H. Sugarbaker in 1980 has shown a benefit in survival especially in patients with gastrointestinal cancer and ovarian cancer. Thailand started to perform this integrated treatment in 2012. A modification of the heart–lung machine was used as the hyperthermic pump for the first few years. Until now, 240 cases have been treated in 7 centers. Although the Thai health care system covers all areas and is easy to access, many surgeons still doubt the benefit and safety of this treatment. This coupled with difficulty in procuring the equipment, and high procedural cost has resulted in few surgeons offering this treatment and fewer patients availing of it. The small group of peritoneal surface malignancy (PSM) surgeons tries to educate all health care providers to understand how it works in an advanced-stage cancer patient and to make this procedure be covered by the national health care policy.